Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an announcement.
Bio-Gene Technology reported strong operational momentum in the December 2025 quarter as it advanced both its Flavocide and Qcide insecticide platforms from foundational R&D into more mature regulatory, formulation and commercial development. The company is prioritising a suite of safety studies and formulation work for Flavocide to support multi-jurisdictional registrations, underpinned by successful pilot-scale manufacturing with Rallis India that provides a clearer pathway to scale-up and future supply agreements. Qcide development continues to benefit from improved plantation yields and biomass processing in Far North Queensland, while its recent approval for listing by the US Organic Materials Review Institute as a botanical pesticide under the USDA National Organic Program strengthens Bio-Gene’s positioning in organic and sustainable agriculture markets and supports additional product formulations. Bio-Gene is also progressing two US Department of Defense-funded Deployed Warfighter Protection programs: a Flavocide-based wearable mosquito protection device that has entered entomological testing with early evidence of efficacy, and a Qcide-based indoor residual spray targeting bed bugs and other pests that is expected to commence following the resolution of administrative delays in the US. Management highlights a refreshed pipeline of eight active product opportunities and expanding international business development, indicating the company is positioned to achieve further technical, regulatory and commercial milestones as demand grows for safer, biologically derived pest control solutions.
The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian agtech company developing next-generation, nature-derived insecticides through its proprietary Flavocide and Qcide platforms, targeting markets including public health, crop protection, consumer pest control and organic, sustainable agriculture. The company partners with global chemical and agricultural businesses and leverages external grant funding to advance regulatory approvals, product development and commercialisation of its biologically based pest control technologies.
Average Trading Volume: 202,798
Technical Sentiment Signal: Buy
Current Market Cap: A$9.15M
Learn more about BGT stock on TipRanks’ Stock Analysis page.